Cannabis in Africa
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Michael H. Daub Attorney at Law 10249 Yellow Circle Drive Suite 102 Minnetonka, Mn 55343
MICHAEL H. DAUB ATTORNEY AT LAW 10249 YELLOW CIRCLE DRIVE SUITE 102 MINNETONKA, MN 55343 TELEPHONE: (612) 333-1943 E-MAIL: [email protected] February 16, 2021 Representative Zack Stephenson 509 State Office Building St. Paul, MN 55155 In Re: HF 600 Dear Representative Stephenson, I am a drug and substance use disorder policy expert. I am grateful for the opportunity to comment on HF 600 which proposes to regulate adult-use cannabis. There are aspects of HF 600 which I support and some that I oppose. Dr. Karen Randall, a Pueblo, Colorado emergency department physician who specializes in cannabis science and medicine states that “the legalization of marijuana has damaged, rather than helped,” her home state. She goes on to state that, “I think the public needs to know that we are not okay...the grand experiment is not going well. I don’t think the public is hearing about this as they should be.” She adds, “State government has not only ignored scientific findings about marijuana’s effects to push sales, but failed in the regulatory responsibility it promised would accompany legislation.” In support of her statements, she focused on high potency cannabis products, a marked increase in medical problems, misguided impressions of cannabis’ benefits, increased homelessness, and a growing population of chronic, cannabis dependent users. Minnesota sits at a crossroads. Cannabis legalization brings with it difficult legal and policy challenges. Although Minnesota partially decriminalized cannabis in 1976, the legalization movement never gained much momentum. In 2014, Minnesota legalized medical cannabis. Although the federal law criminalizing cannabis, the Controlled Substances Act of 1970 (“CSA”) remains in effect, the budding experiment to legalize cannabis has not withered on the vine. -
Initial Considerations for the Creation of an Inter-Regional Industrial Hemp Value Chain Between Malawi and South Africa
A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Lowitt, Sandy Working Paper Initial considerations for the creation of an inter- regional industrial hemp value chain between Malawi and South Africa WIDER Working Paper, No. 2020/23 Provided in Cooperation with: United Nations University (UNU), World Institute for Development Economics Research (WIDER) Suggested Citation: Lowitt, Sandy (2020) : Initial considerations for the creation of an inter- regional industrial hemp value chain between Malawi and South Africa, WIDER Working Paper, No. 2020/23, ISBN 978-92-9256-780-4, The United Nations University World Institute for Development Economics Research (UNU-WIDER), Helsinki, http://dx.doi.org/10.35188/UNU-WIDER/2020/780-4 This Version is available at: http://hdl.handle.net/10419/229247 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. -
Extracts and Tinctures of Cannabis
WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. -
Methods to Assess Cannabis Consumption in Population Surveys
QHRXXX10.1177/1049732318820523Qualitative Health ResearchGoodman et al. 820523research-article2019 Research Article Qualitative Health Research 1 –9 Methods to Assess Cannabis © The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissions Consumption in Population Surveys: DOI:https://doi.org/10.1177/1049732318820523 10.1177/1049732318820523 Results of Cognitive Interviewing journals.sagepub.com/home/qhr Samantha Goodman1 , Cesar Leos-Toro1, and David Hammond1 Abstract The Cannabis Act legalized the possession and sale of nonmedical cannabis in Canada on October 17, 2018. Evaluating the impact of cannabis legalization requires a more thorough understanding than is provided by most existing measures of cannabis use. The aim of this study was to pretest a range of cannabis consumption measures used in a population- based survey and to share insights gained in the process. Cognitive interviewing was conducted among 10 cannabis users aged ≥16 years. Comprehension and self-reporting of consumption types and amounts, sources of purchase, and cannabinoid levels were examined. Findings revealed areas for improvement in a number of survey items, including unclear wording and reference images. Identified issues were used to improve the survey for use in the International Cannabis Policy Study. The authors discuss important principles (e.g., use of visual cues, user-selected units, and time frames) that should be adopted when assessing cannabis use in population-based studies. Keywords cannabis; cognitive interview; prevalence; measurement; qualitative; Canada Background cannabis consumption in terms of the number of times cannabis is used within a particular month, day or week, Cannabis (also referred to as “marijuana,” “pot,” “weed,” or the typical amount used on each occasion (e.g., etc.) is the most frequently used illicit substance world- Canadian Cannabis Survey; Advanis, 2017). -
Report on Medical Cannabis Price Study
Minnesota Department of Health Office of Medical Cannabis Report on Medical Cannabis Price Study Version 1.2 Submitted by: Bill Brown, Principal Yoko McCarthy, Manager BerryDunn 2211 Congress Street Portland, ME 04102 Table of Contents Table of Contents ......................................................................................................................... i 1.0 Introduction .......................................................................................................................... 1 1.1 Project Background .......................................................................................................... 1 1.2 Office of Medical Cannabis (OMC) ................................................................................... 2 1.3 Registered Medical Cannabis Manufacturers.................................................................... 2 1.4 Products Offered in Minnesota and Definitions ................................................................. 3 2.0 Purpose and Scope .............................................................................................................. 4 2.1 Purpose ............................................................................................................................ 4 2.2 Scope ............................................................................................................................... 4 3.0 Results ................................................................................................................................ -
1 1 Date: 15 April 2006 MID-TERM EVALUATION REPORT Project Number: TDMAR03G56 Project Title: Demand Reduction Programme for Maur
1 Date: 15 April 2006 MID-TERM EVALUATION REPORT Project Number: TDMAR03G56 Project title: Demand Reduction Programme for Mauritius Thematic area: Prevention and Reduction of Drug Abuse Country: Mauritius Report of the Evaluation team Dr. Reychad Abdool, Drug Abuse and HIV/AIDS Adviser, Africa, UNODC Regional Office for Eastern Africa, Nairobi, Kenya, Dr. Fayzal T. Sulliman, National Programme Manager, Mauritius. 1 2 CONTENTS Page TABLE OF CONTENTS 2 LIST OF ACRONYMS 4 EXECUTIVE SUMMARY 5 1. INTRODUCTION 9 1.1. Background and Context. 9 1.2. Purpose and Objective of the Evaluation 10 1.3. Executing Modality 10 1.4. Scope of the Evaluation 11 1.5. Evaluation Methodology 11 1.6.EvaluationTeam Composition 12 1.7. Limitations 12 2. MAJOR FINDINGS 12 2.1. Overall performance assessment (Appropriateness, Relevance, 12 Effectiveness, Efficiency) 2.2. Attainment of Objectives 13 2.3. Achievement of Programme/Project Results and outputs 14 2.4. Implementation (Operational Plan, Monitoring and Backstopping) 15 2.5. Institutional and Management Arrangements 15 3. OUTCOMES, IMPACTS and SUSTAINABILITY 15 3.1. Outcomes 15 3.2. Impacts 16 3.3. Sustainability 16 4. MAJOR LESSONS LEARNED ANDBESTPRACTICES 17 2 3 5. RECOMMENDATIONS 17 5.1. Issues resolved during evaluation. 18 5.2. Actions/decisions recommended. 18 6. OVERALL CONCLUSIONS 20 . Annexes 1. Terms of Reference. 2. Organizations and places visited and persons met. 3 4 LIST OF ACRONYMS ( In alphabetical order) AU African Union C ATR Centre d’Accueil de Terre Rouge CYC Correctional Youth Centre -
Programme & Abstracts
The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday. -
International Bureau for Children's Rights (IBCR)
Making Children’s Rights Work in North Africa: Country Profiles on Algeria, Egypt, Libya, Morocco Country Profiles on Algeria, Egypt, Libya, Morocco and Tunisia and Tunisia Making Children’s Rights Work in North Africa:Making Children’s Rights Work Making Children’s Rights Work in North Africa: Country Profiles on Algeria, Egypt, Libya, Morocco and Tunisia The first version of this report was posted on IBCR’s website in March 2007. This second version has been reedited in August 2007. International Bureau for Children’s Rights (IBCR) Created in 1994 and based in Montreal, Canada, the International Bureau for Children’s Rights (IBCR) is an international non- governmental organisation (INGO) with special consultative status with the United Nations Economic and Social Council (ECOSOC). IBCR offers its expertise, particularly in the legal sector, to contribute to the protection and promotion of children’s rights in conformity with the 1989 United Nations Convention on the Rights of the Child (CRC) and its Optional Protocols. The expertise of IBCR resides in the sharing of knowledge and good practices and in the development of tools and models to inspire implementation of children’s rights. IBCR’s expertise also lies in raising awareness about children’s rights to persuade decision-makers to adopt laws and programmes that more effectively respect the rights of the child. In recent years, IBCR’s main successes include its exceptional contribution to the elaboration of the Guidelines on Justice in Matters Involving Child Victims and Witnesses of Crime as well as their adoption by the United Nations Economic and Social Council (ECOSOC Res. -
The Canadian Cannabis Story
A Generational Investment Opportunity THE CANADIAN CANNABIS STORY JOIN THE CONVERSATION / Echelon Wealth Partners echelonpartners.com TABLE OF CONTENTS 3 The Canadian Cannabis Story: A Generational Investment Opportunity 4 Cannabis: A Brief History 5 The Many Forms of Cannabis 5 An Increase in Legal Cannabis-based Products 5 Medical Use 8 Cannabis as an Opiod Alternative 11 Cannabis and Canada: A Strong Growth Story 14 A Global Cannabis Boom: The Next Stage 17 Canadian Cannabis Stocks - An Investment Opportunity to Consider 19 Endnotes echelonpartners.com 2 The Canadian Cannabis Story: A Generational Investment Opportunity THE CANADIAN CANNABIS STORY: A GENERATIONAL INVESTMENT OPPORTUNITY By Echelon Wealth Partners The Canadian Cannabis Story aims to provide readers with a comprehensive look at the cannabis market in Canada through its history, growth, and various production sectors to illuminate the investment opportunity this sector will afford in a rapidly growing global market. The increasing trend in cannabis decriminalization and legalization, both in North America and around the world, has awakened the interest of the investment community. The unique and potential medicinal properties of cannabis and its versatility for other commercial uses are considered the harbingers of an investment with significant growth potential. Canada legalized marijuana for recreational use on October 17, 2018 echelonpartners.com 3 The Canadian Cannabis Story: A Generational Investment Opportunity CANNABIS A Brief History Marijuana is produced from the flower and leaves of cannabis plants, which grow naturally in humid temperate conditions on all continents.1 The two most important varieties of the cannabis plant are sativa and indica, with hemp being a specific species of the sativa plant. -
1.3 Cannabis Market
1.3 Cannabis market 1.3.1 Summary trend overview 1.3.2 Production UNODC estimates that between 200,000-641,800 ha The total estimated area for outdoor production of can- were used for outdoor cannabis cultivation in 2008. nabis in 2008 ranges from 200,000-641,800 ha. The There are high levels of uncertainty in cultivation esti- total cannabis herb production is estimated to range mates as cannabis can be grown - indoors or outdoors - from 13,300-66,100 mt and the production of cannabis in most countries in the world. Therefore, it is not resin from 2,200-9,900 mt. Due to high levels of uncer- possible to produce more precise data, as is done for tainty in estimating cultivation, it is not possible to opiates and cocaine. The total cannabis herb production produce more precise data, as is done for opiates and is estimated to range from 13,300-66,100 mt, and for coca/cocaine. cannabis resin, the estimated production range is 2,200- 9,900 mt. This chapter shows the information that is available and gives an indication of the extent of global cannabis cul- Total cannabis herb seizures increased somewhat in 2007 tivation and production. Minimum and maximum to reach a total of 5,600 mt. As in 2006, the majority of levels of production and cultivation are explored by cannabis herb seizures in 2007 were reported from applying four methods. One method is based on reported Mexico and the USA. Cannabis resin seizures also cultivation and production, the second is based on sei- increased to some 1,300 mt, with most seizures reported zures of cannabis, and the third and fourth method are by countries in West and Central Europe. -
CANNABIS CONSUMPTION AREAS (WHMC 5.70.041) Business Name
CANNABIS CONSUMPTION AREA BUSINESS LICENSE APPLICATION Department of Public Works 8300 Santa Monica Boulevard West Hollywood, CA 90069 (323) 848-6375 Cannabis Consumption Area with On-Site Adult-Use Retail shall mean and include: a licensed premise where cannabis may be purchased (for on-site consumption only) and consumed by persons 21 years of age and over. A cannabis consumption area must be limited to one of the following uses: 1. Consumption of cannabis by smoking, vaping, and ingesting edible products. 2. Consumption of cannabis edible products by ingestion only. Only the top eight scoring applicants in the Cannabis Consumption Area Business License category, as determined by the Screening Application process outlined in WHMC 5.70.035, and adopted by the Application Evaluation Committee on February 7, 2019, are eligible to apply for an Cannabis Consumption Area Business License with the City of West Hollywood and shall use the following application packet to apply: SUBMIT THE FOLLOWING ITEMS. Failure to submit the required information will constitute an incomplete application and will not be accepted by the Department of Public Works. Smoking, Vaping, Edibles Edibles Only Application Checklist Forms Included in the Application Packet Items to be Provided by the Applicant Provided N/A Completed Applicant/Owner Information Form Valid Government-issued ID or Drivers License (for all owners as defined in Section C)5 Acknowledgement of Operating Requirements California State Cannabis License (if already obtained) Cannabis Business Indemnity Agreement Form Detailed Business Floor Plan Agency Approvals for Issuance of Final License Neighborhood Layout (Elevations and Overhead)4 Notarized Owner's Affidavit Interior and Exterior Design Renderings1 Additional Information Requested Odor Control Plan Completed Request for Live Scan Service for all owners (as defined in Section C)5 and managers Approved Hazard Analysis Plan (if required)3 Live Scan Results Release Authorization Form Security Operations Plan1,2 Proof of Business Ownership (i.e. -
Medical Cannabis in Minnesota
Medical Cannabis in Minnesota Tom Arneson, MD, MPH | Research Manager MN Employers Workers Comp. Alliance: June 8, 2017 Office of Medical Cannabis • 2014: MN became 22 nd state with full medical cannabis program Recreational and Medical (8) Medical (21) Low THC/High CBD Products (15) 6/14/2017 2 Office of Medical Cannabis However: • State medical cannabis programs are illegal under current federal law 6/14/2017 mn.gov/medicalcannabis 3 Office of Medical Cannabis Minnesota's program is different from most others • No smokeable or plant form marijuana (only liquids and oils in capsule, tincture, or vaporized form. Topical preparations of oils starting in August, 2017) • Commitment to learning from experience with the program (reports and observational studies on effectiveness, side effects, etc.) 6/14/2017 mn.gov/medicalcannabis 4 Office of Medical Cannabis Brief History • Documentation of therapeutic use of cannabis for thousands of years in India and China • 1839: William O’Shaughnessy – Irish physician working in India studied medical uses of cannabis; introduced it to European medicine when he returned to London • 1894: Queen Victoria’s physician praises therapeutic value of cannabis in the first issue of Lancet . (Queen Victoria was treated with cannabis for dysmenorrhea) • Sir William Osler, one of the founders of Johns Hopkins School of Medicine wrote the famous first textbook of internal medicine in 1892. it included his assessment that cannabis was the best treatment for migraine headache. 6/14/2017 mn.gov/medicalcannabis 5 Office of Medical Cannabis History (continued) • Recreational use of cannabis started in the Southwest around 1900, introduced by Mexican workers crossing the border • American doctors wrote millions of prescriptions for cannabis each year in the 1920s • 1937: Marijuana Tax Act: small annual tax on all involved with commercial use of cannabis, including physicians.